|
Session 114
Poster Abstracts
Emergence of HIV Drug Resistance in Developing Nations
Tuesday, 1 - 4 pm
Poster Hall |
640
 |
Antiretroviral Drug Resistance among Drug-naive HIV-1 Recently Infected Individuals in South Africa
Visva Pillay*1, J Ledwaba1, G Hunt1, M Rakgotho1, B Singh1, L Makubalo2, A Puren1, and L Morris1
1Natl Inst for Communicable Diseases, Johannesburg, South Africa and 2Dept of Hlth, South Africa |
| 641 |
ART Drug Resistance Mutations in ART-experienced and Newly Initiated Patients in Nigeria
E Idigbe1, B Chaplin2, E Ekong2, J Idoko3, I Adewole4, G Eisen2, J L Sankalé2, R Murphy5, Phyllis Kanki*2, and APIN Plus/Harvard PEPFAR Team
1Natl Inst of Med Res, Lagos, Nigeria; 2Harvard PEPFAR, Harvard Sch of Publ Hlth, Boston, MA, US; 3Jos Univ Teaching Hosp, Nigeria; 4Univ Coll Hosp, Ibadan, Nigeria; and 5Northwestern University, Chicago, IL, USA |
| 642 |
Emergence and Evolution of Drug Resistance in the Absence of Viral Load Monitoring during 48 Weeks of Combivir/Tenofovir within the DART Trial
Deenan Pillay*1, C Kityo2, V Robertson3, F Lyagoba4, D Dunn5, S Tugume2, J Hakim3, P Munderi4, C Gilks6, P Kaleebu4, and DART Virology Group and Trial Team
1Univ Coll London, UK; 2Joint Clin Res Ctr, Kampala, Uganda; 3Univ of Zimbabwe; 4Med Res Council AIDS Unit, Uganda; 5Med Res Council Clin Trials Unit, London, UK; and 6Imperial Coll, London, UK |
643
|
Detection of Drug Resistance by Population Sequencing and Allele Specific PCR for K103N after Nevirapine-based HAART in Subtype C HIV-1 in Zimbabwe
Johanna Ledwaba*1, V Pillay1, S Dalai2, S Kassaye2, L Zijenah3, G Kadzirange3, M Mucheche3, S Loubser1, L Morris1, and K David2
1Natl Inst for Communicable Diseases, Johannesburg, South Africa; 2Stanford Univ, CA, US; and 3Univ of Zimbabwe, Harare |
644
|
Pre-HAART Drug Resistance Mutations in Subtype C HIV-1 in Zimbabwe
Seble Kassaye*1, V Pillay2, J Ledwaba2, S Dalai1, L Zijenah3, G Kadzirange3, G Musingwini3, L Morris2, and D Katzenstein1
1Stanford Univ, CA, US; 2Natl Inst for Communicable Diseases, Johannesburg, South Africa; and 3Univ of Zimbabwe, Harare |
645
|
Influence of Genotypic Drug-resistance Mutation on Clinical and Immunological Outcomes in HIV-infected Adults Receiving ART in Abidjan, Côte d’Ivoire
Catherine Seyler*1,2, Catherine Seyler*1,2, C Adjé-Touré3, N Dakoury-Dogbo2, D Gabillard1, E Messou2, S Touré2, F Rouet4, R Marlink5, M Nolan3, X Anglaret1,2, and X Anglaret1,2
1INSERM U593, Univ Victor Segalen, Bordeaux, France; 2PACCI and ACONDA, Abidjan, Côte d'Ivoire; 3Project RETRO-CI, Abidjan, Côte d'Ivoire; 4CeDReS, Ctr Hosp Univ de Treichville, Abidjan, Côte d'Ivoire; and 5Elizabeth Glaser Pediatric AIDS Fndn, Santa Monica, CA, US |
646
|
Low Rate of Resistance to Antiretroviral Drugs 6 Months after HAART Initiation in HIV-1-infected Sub-Saharan African: The ANRS 1269 TRIVACAN Trial
Marie-Laure Chaix*1, F Rouet2, T D Toni2, C Danel3, R Moh3, D Gabillard4, R Salamon4, E Bissagnene5, X Anglaret4, and C Rouzioux1
1Ctr Hosp Univ Necker, Paris, France; 2CeDReS, Ctr Hosp Univ de Treichville, Abidjan, Côte d'Ivoire; 3PACCI, Abidjan, Côte d'Ivoire; 4INSERM 593, Univ Victor Segalen Bordeaux 2, France; and 5Ctr Hosp Univ Treichville, Abidjan, Côte d'Ivoire |
647
|
Prevalence of Treatment Failure and Drug Resistance among Treatment-experienced HIV-1-infected Individuals at a Tertairy HIV Referral Center in South India
Sunil Solomon*1,2, Sunil Solomon*1,2, P Balakrishnan2, N Shetty3, A Cecelia2, V Madhavan2, A Ganesh2, N Kumarasamy2, D Celentano1, S Solomon2, and J Gallant4
1Johns Hopkins Univ Bloomberg Sch of Publ Hlth, Baltimore, MD, US; 2YRGCARE, Chennai, India; 3Columbia Univ Mailman Sch of Publ Hlth, New York, NY, US; and 4Johns Hopkins Univ Sch of Med, Baltimore, MD, US |
|
